UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): May 23, 2017
(Exact Name of
Registrant as Specified in Charter)
|
Nevada
|
|
333-198621
|
|
46-3312262
|
|
(State or other
jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
3279 Hardee
Avenue
Atlanta, Georgia
|
|
|
|
30341
|
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Harvey Kesner,
Esq.
Arthur S. Marcus,
Esq.
Sichenzia
Ross Friedman Ference LLP
61 Broadway,
32nd Floor
New York, New
York 10006
(212)
930-9700
(212) 930-9725
(fax)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d 2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item
3.01 Notice of Delisting or Failure to
Satisfy a Continued Listing Rule or Standard; Transfer of
Listing.
On May 17, 2017, Medovex
Corp. (the “Company”) received a letter from the
Listing Qualifications Department of the NASDAQ Stock Market (the
“Staff”) notifying the Company that the
stockholders’ equity of $1,895,299 as reported in the
Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017 was below the minimum stockholders’ equity of
$2,500,000 required for continued listing on the NASDAQ Capital
Market as set forth in NASDAQ listing rule 5550(b)(1) (the
“Rule”).
The Company has the right to
request an appeal of this determination by May 24, 2017 or its
common stock will be suspended at the opening of business on May
26, 2017. The Company intends to request an appeal of the
determination within the required time period. There can be no
assurance that the appeal will be granted.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDOVEX
CORP.
|
|
|
|
|
Date: May 23,
2017
|
By: /s/ Jarrett Gorlin
Jarrett Gorlin
Chief Executive
Officer
|